DeepMed Research

Cenerimod

Generic Name: Cenerimod

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₁N_₃O_₅

CAS Number: 1262414-04-9

Unique Ingredient Identifier: Y333RS1786

Background: Cenerimod has been used in trials studying the treatment of Systemic Lupus Erythematosus.

Clinical Trials

Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus

Phase 3

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Cenerimod

First Posted Date: 2024-06-26

Last Posted Date: 2025-04-25

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 680

Registration Number: NCT06475742

Locations: 🇨🇱
Hospital San José de Victoria, Victoria, Chile
🇨🇿
iMedica s.r.o., Brno, Czechia
🇨🇿
Institute of Rheumatology Prague, Prague, Czechia

and more 38 locations

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus

Phase 3

Recruiting

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Cenerimod
Drug: Placebo

First Posted Date: 2023-01-05

Last Posted Date: 2025-04-25

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 420

Registration Number: NCT05672576

Locations: 🇬🇪
Tbilisi Institute of Medicine, Tbilisi, Georgia
🇬🇪
Ltd. Mtskheta Street Clinic, Tbilisi, Georgia
🇬🇪
The First Medical Center Ltd., Tbilisi, Georgia

and more 139 locations

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

Phase 3

Recruiting

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: Placebo
Drug: Cenerimod

First Posted Date: 2022-12-13

Last Posted Date: 2025-03-20

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 420

Registration Number: NCT05648500

Locations: 🇧🇬
DCC Equita EOOD, Varna, Bulgaria
🇺🇸
Allen Arthritis, Allen, Texas, United States
🇧🇷
CPClin - Centro de Pesquisas Clínicas, São Paulo, Brazil

and more 144 locations

The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics

Phase 1

Completed

Conditions: Healthy
Renal Impairment

Interventions: Drug: Cenerimod

First Posted Date: 2021-08-13

Last Posted Date: 2023-08-21

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 16

Registration Number: NCT05004311

Locations: 🇵🇹
BlueClinical Phase 1 Hospital de Prelado, Porto, Portugal

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of a Single Dose of Cenerimod

Phase 1

Recruiting

Conditions: Healthy
Hepatic Impairment

Interventions: Drug: Cenerimod

First Posted Date: 2021-03-29

Last Posted Date: 2023-11-03

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 24

Registration Number: NCT04819464

Locations: 🇵🇹
BlueClinical Phase 1 Hospital de Prelado, Porto, Portugal
🇭🇺
CRU Hungary, Kistarcsa, Hungary

To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men.

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Combined oral contraceptives (COC)
Drug: Moxifloxacin 400mg
Drug: Matching Placebo
Drug: Cenerimod 0.5 mg
Other: Charcoal, activated
Drug: Cenerimod 4 mg

First Posted Date: 2020-02-05

Last Posted Date: 2022-11-16

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 97

Registration Number: NCT04255277

Locations: 🇫🇷
Site 1, Rennes, France

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Matching Placebo
Drug: Cenerimod

First Posted Date: 2019-08-09

Last Posted Date: 2020-04-27

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 20

Registration Number: NCT04052360

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Cenerimod 0.5 mg
Drug: Cenerimod 1 mg
Drug: Placebo
Drug: Cenerimod 2 mg
Drug: Cenerimod 4 mg
Drug: cenerimod 2 mg (ex-4 mg)

First Posted Date: 2018-11-15

Last Posted Date: 2023-09-22

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 427

Registration Number: NCT03742037

Locations: 🇺🇸
North Georgia Rheumatology Group - Duluth, Lawrenceville, Georgia, United States
🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇫🇷
Hôpital Haut-Lévêque, Pessac, France

and more 145 locations

A Study to Evaluate Cenerimod in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: Cenerimod

First Posted Date: 2016-09-26

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 6

Registration Number: NCT02914223

Locations: 🇳🇱
PRA Health Science, Groningen, Netherlands

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Cenerimod
Drug: Matching placebo

First Posted Date: 2015-06-16

Last Posted Date: 2020-02-26

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 105

Registration Number: NCT02472795

Locations: 🇺🇦
Investigator Site, Zaporizhia, Ukraine

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy